Australia's most trusted
source of pharma news
Saturday, 14 June 2025
Posted 11 June 2025 PM
One of Chimeric Therapeutics’ CAR T therapies has been granted a fast track designation from the FDA, marking the biggest regulatory achievement for the ASX listed company yet.
Led by Novartis Australia’s former Head of Strategic Access, Rebecca McQualter, the Melbourne-based company has two autologous CAR T cell therapies and an allogenic NK cell therapy currently being assessed across multiple different disease areas in oncology with four clinical stage programs.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.